BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 27473823)

  • 21. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.
    Liu Y; Lu J; Zhang Z; Zhu L; Dong S; Guo G; Li R; Nan Y; Yu K; Zhong Y; Huang Q
    Cell Death Dis; 2017 Aug; 8(8):e3022. PubMed ID: 29048430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-β1 regulating miR-205/miR-195 expression affects the TGF-β signal pathway by respectively targeting SMAD2/SMAD7.
    Duan Y; Chen Q
    Oncol Rep; 2016 Oct; 36(4):1837-44. PubMed ID: 27574009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next generation sequencing analysis of miRNAs: MiR-127-3p inhibits glioblastoma proliferation and activates TGF-β signaling by targeting SKI.
    Jiang H; Jin C; Liu J; Hua D; Zhou F; Lou X; Zhao N; Lan Q; Huang Q; Yoon JG; Zheng S; Lin B
    OMICS; 2014 Mar; 18(3):196-206. PubMed ID: 24517116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear receptor TLX inhibits TGF-β signaling in glioblastoma.
    Johansson E; Zhai Q; Zeng ZJ; Yoshida T; Funa K
    Exp Cell Res; 2016 May; 343(2):118-125. PubMed ID: 27048878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A tumor-promoting role for soluble TβRIII in glioblastoma.
    Burghardt I; Schroeder JJ; Weiss T; Gramatzki D; Weller M
    Mol Cell Biochem; 2021 Aug; 476(8):2963-2973. PubMed ID: 33772427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.
    Roy LO; Poirier MB; Fortin D
    Invest New Drugs; 2015 Oct; 33(5):1020-31. PubMed ID: 26271735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
    Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
    Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of extracellular signal-regulated kinase by TGF-beta1 via TbetaRII and Smad7 dependent mechanisms in human bronchial epithelial BEP2D cells.
    Huo YY; Hu YC; He XR; Wang Y; Song BQ; Zhou PK; Zhu MX; Li G; Wu DC
    Cell Biol Toxicol; 2007 Mar; 23(2):113-28. PubMed ID: 17096210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways.
    Han M; Wang F; Gu Y; Pei X; Guo G; Yu C; Li L; Zhu M; Xiong Y; Wang Y
    Oncol Rep; 2016 Jan; 35(1):73-80. PubMed ID: 26531758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HSP47 Promotes Glioblastoma Stemlike Cell Survival by Modulating Tumor Microenvironment Extracellular Matrix through TGF-β Pathway.
    Jiang X; Zhou T; Wang Z; Qi B; Xia H
    ACS Chem Neurosci; 2017 Jan; 8(1):128-134. PubMed ID: 27696866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
    El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
    Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
    Miekus K; Kijowski J; Sekuła M; Majka M
    Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
    Nana AW; Yang PM; Lin HY
    Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer.
    Heider TR; Lyman S; Schoonhoven R; Behrns KE
    Ann Surg; 2007 Jul; 246(1):61-8. PubMed ID: 17592292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transforming growth factor-beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptides.
    Zarranz-Ventura J; Fernández-Robredo P; Recalde S; Salinas-Alamán A; Borrás-Cuesta F; Dotor J; García-Layana A
    PLoS One; 2013; 8(5):e65434. PubMed ID: 23741494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.
    Hardee ME; Marciscano AE; Medina-Ramirez CM; Zagzag D; Narayana A; Lonning SM; Barcellos-Hoff MH
    Cancer Res; 2012 Aug; 72(16):4119-29. PubMed ID: 22693253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.